title: Rituximab maintenance therapy of relapsed or refractory follicular lymphoma, with longer follow-up: no proven impact on survival.
abstract: Long-term follow-up data from a clinical trial including 334 patients that compared single-agent maintenance therapy with rituximab versus watchful waiting showed no statistically significant increase in survival time among patients with relapsed or refractory follicular lymphoma.
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008134:Long-Term Care; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D015201:Meta-Analysis as Topic; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D000069283:Rituximab; D013534:Survival; D057832:Watchful Waiting
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab